ArticleAddiction science & clinical practice2026
24-48 h initiation by transdermal buprenorphine for the treatment of opioid use disorder in the inpatient setting: a retrospective chart review.
Article in Addiction science & clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBuprenorphine (Bup) is a first-line medication for opioid use disorder (OUD) that carries risk of precipitated withdrawal (PW) with ongoing need for rapid and effective initiation strategies. We report a novel approach to low-dose initiation using transdermal Bup patches (TD-Bup) and characterize the efficacy and tolerability of 24 h and 48 h TD-Bup initiation protocols for Bup as a medication for OUD (MOUD).
methodsWe conducted a retrospective chart review using data extracted from paper and electronic medical records of adult inpatients with OUD admitted to Vancouver General Hospital between January 2022 and October 2023. Eligible patients were started on low-dose transdermal buprenorphine (TD-Bup) initiation protocols. The intervention involved sequenced application of TD-Bup patches reaching a total of 12 patches (240 µg/h) over 24 to 48 hours, with continuation of full opioid agonists. Protocol variants included: 6 patches q24h for 48 hours, 6 patches q12h for 24 hours, and 4 patches q8h for 24 hours. Primary outcomes were the rate of successful initiation onto therapeutic doses of sublingual or extended-release depot Bup, and the incidence of opioid withdrawal.
resultsSeventy five patients were identified. Fifty five (73%) were successfully initiated and discharged on Bup and the most common reasons for unsuccessful initiation were preference to switch to another medication for OUD (n = 11) and withdrawal (n = 6). There was no significant difference between the protocol variants for successful initiation (p = 0.191). Adverse events (agitation, increased pain, insomnia, pruritus) were reported in 5 dropouts. Only 28 patients had sufficient Clinical Opioid Withdrawal Scale (COWS) scores to allow for objective assessment of withdrawal, with the remainder evaluated from full chart review. Nineteen patients had COWS score elevation > 6 and/or any narrative documentation of withdrawal. Three patients were felt to represent probable PW. No relationships were found between withdrawals and protocol variant (p = 0.621) or successful initiation (p = 0.082). All-cause withdrawals were associated with self-directed discharges (p = 0.042). CONCLUSIONS AND RELEVANCE: Rapid low-dose buprenorphine initiation with TD-Bup appears feasible with relatively low risk of withdrawals and PW, although a weakness is the vulnerability to underdosing patients with full opioid agonists resulting in opioid deficit withdrawal. Further prospective evaluation of d rapid low-dose buprenorphine initiation with TD-Bup against other evidence-based contemporary Bup MOUD initiations is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.